Human UDP-galactose 4′-epimerase (GALE) is required for cell-surface glycome structure and function

Glycan biosynthesis relies on nucleotide sugars (NSs), abundant metabolites that serve as monosaccharide donors for glycosyltransferases. In vivo, signal-dependent fluctuations in NS levels are required to maintain normal cell physiology and are dysregulated in disease. However, how mammalian cells regulate NS levels and pathway flux remains largely uncharacterized. To address this knowledge gap, here we examined UDP-galactose 4′-epimerase (GALE), which interconverts two pairs of essential NSs. Using immunoblotting, flow cytometry, and LC-MS–based glycolipid and glycan profiling, we found that CRISPR/Cas9-mediated GALE deletion in human cells triggers major imbalances in NSs and dramatic changes in glycolipids and glycoproteins, including a subset of integrins and the cell-surface death receptor FS-7-associated surface antigen. In particular, we observed substantial decreases in total sialic acid, galactose, and GalNAc levels in glycans. These changes also directly impacted cell signaling, as GALE−/− cells exhibited FS-7-associated surface antigen ligand-induced apoptosis. Our results reveal a role of GALE-mediated NS regulation in death receptor signaling and may have implications for the molecular etiology of illnesses characterized by NS imbalances, including galactosemia and metabolic syndrome.

Glycosylation, the enzymatic attachment of carbohydrates to proteins, lipids, and other biomolecules, is an abundant modification conserved across all clades of life (1). In mammals, glycosylation influences nearly every cell biological process, including protein quality control and secretion, adhesion and migration, and host–pathogen interactions (2–4). Consistent with this central role in mammalian physiology, aberrant glycosylation contributes to the pathology of myriad human diseases, such as developmental defects, diabetes, obesity and metabolic syndrome, cancer, neurodegeneration, and atherosclerosis (5–13).

Virtually all glycoconjugates are assembled from nucleotide-sugars (NSs), metabolites that donate “activated” monosaccharides to glycosyltransferases (2). In recent years, several groups observed that specific stimuli or signaling events, such as feeding or ischemic stress, trigger increased NS biosynthesis in mammalian cells, likely facilitating protein secretion and supporting the remodeling of cell-surface glycans (14, 15). Many glycosyltransferases are sensitive to NS concentrations, so changes in NS levels affect not only bulk levels of glycosylation but also specific glycosyltransferase substrate choices (16–21). These observations highlight the critical role of NS regulation in shaping downstream glycoconjugate biosynthesis and function. However, although the biochemistry of NS biosynthetic enzymes is well-understood, little is known about how cells regulate flux through NS metabolic pathways in response to signals or disease states. Furthermore, the impact of NS fluctuations on key glycosylation pathways and downstream cellular phenotypes is poorly understood, representing a major knowledge gap in cell biology.

As a first step toward understanding the mechanisms and functions of human NS regulation, we focused on UDP-galactose 4′-epimerase (GALE) as a model enzyme. Mammalian GALE interconverts two pairs of substrates: the hexose NSs UDP-Glc/UDP-Gal and the corresponding hexosamines NSs UDP-GlcNAc and UDP-GalNAc (Fig. 1A) (22–24). Through these reversible epimerizations, human GALE balances the pools of four NSs essential for the biosynthesis of thousands of glycoproteins and glycolipids (2, 23, 24). Interestingly, however, GALE is not absolutely required for the biosynthesis of any of its four substrates, each of which could hypothetically be derived from independent salvage or de novo metabolic routes in nutrient-replete cells (2, 22). Because it acts only by interconverting existing NSs, GALE is an excellent model enzyme to study the role of dynamically balancing NS pools in cell physiology. Furthermore, GALE is significant to...
Human GALE is required for glycome function

To characterize the role of GALE in cell physiology, we used CRISPR/Cas9 methods to create GALE−/− human cell systems. Our results reveal that GALE is required to maintain NS levels and to biosynthesize a wide range of glycoproteins and glycolipids, even under nutrient-replete conditions. In particular, we show that GALE is essential for N-glycosylation of several cell-

![Diagram A](image)

**A**

- GalNAc → GalNAc-1P → UDP-GalNAc
- GalK2 → GalK1 → GALT
- AGX1
- HBP → UDP-GlcNAc
- GALE
- UGPB → Glc

**B**

- gRNA: Control Gal-1P UDP-Gal
- Clone: A B A A A A B
- 37°C 50°C

**C**

- Viability (% of control)
  - 250 μM Gal
  - 500 μM Gal

**D**

- HeLa
- Control A B GALE-1A GALE-3B
- Mannitol Gal
- UDP-Gal (umol/mg protein)

- 293T
- Control A B GALE-1A GALE-2A
- Mannitol Gal
- UDP-Gal (umol/mg protein)

**E**

- Control GALE−/−
- Gal: + + - - + + - -
- 37°C 50°C 50°C
- GALK1 GALK2 tubulin
surface proteins, including a subset of integrin cell adhesion proteins and the apoptotic death receptor Fas. Moreover, GALE deletion results in Fas hypoglycosylation and hypersensitivity to Fas ligand (FasL)–induced cell death, highlighting a previously unknown function of NS metabolism in apoptotic pathways. Our results reveal a requirement for human GALE in supporting glycoconjugate biosynthesis and cell-surface signaling and establish loss-of-function culture systems as a powerful tool for dissecting the role of NS regulation in human cell biology.

Results
Human GALE is required to balance NS levels

GALE is the final enzyme in the Leloir pathway, a highly conserved metabolic route for the assimilation of Gal (Fig. 1A, bottom) (30). To determine the role of GALE in NS metabolism and glycoconjugate biosynthesis, we used CRISPR/Cas9 methods to construct multiple, single-cell-derived GALE−/− clones from human cell lines and confirmed successful ablation of GALE protein (Fig. 1B). Based on prior studies of the Leloir pathway in human patients and experimental model systems (31, 32), we hypothesized that GALE−/− cells might display NS imbalances under standard culture conditions and/or in the presence of supplementary Gal. In particular, Gal consumption is closely tied to adverse symptoms in galactosemic patients and laboratory models (33, 34). Therefore, we sought to determine the impact of Gal on viability and NS metabolism in our cell models. Gal supplementation did not impair cell viability in control or GALE−/− cells (Fig. 1C). However, both GALE−/− HeLa and 293T cells accumulated high levels of UDP-Gal in the presence of supplementary Gal, whereas control cells showed only a modest increase (Fig. 1D, left panels). We concluded that GALE is required to maintain normal NS levels in nutrient-replete human cells in the absence or presence of supplementary Gal.

Interestingly, GALE−/− cells also exhibited reduced basal levels of UDP-GalNAc, which was partially rescued by Gal addition in HeLa (but not 293T) cells (Fig. 1D, right panels). This effect of Gal was unexpected because there is no known human biosynthetic route to produce UDP-GalNAc from Gal. Therefore, we examined the expression of the GalNAc salvage pathway galactokinas GALK1 and GALK2 in HeLa cells to determine whether Gal supplementation or GALE genotype might indirectly impact GalNAc salvage. However, neither GALE deletion nor Gal supplementation affected GALK1 or 2 levels in HeLa cells (Fig. 1E). These results indicate that Gal supplementation increases UDP-GalNAc levels through an unknown but GALE- and Gal-dependent mechanism in HeLa cells.

GALE is required for glycoprotein and glycolipid biosynthesis

Given the major NS imbalances observed in GALE−/− cells (Fig. 1D), we hypothesized that they might display defects in the biosynthesis of glycoproteins and glycolipids containing Gal or GalNAc, such as mucin-type O-glycoproteins and gangliosides (35–37). Furthermore, a reduction in Gal/GalNAc moieties is predicted to decrease terminal glycan structures such as sialic acids, which are typically added to Gal or GalNAc residues of mature glycans (38). Flow cytometry assays with jacalin (a lectin that binds the Galβ1–3GalNAc Thomsen–Friedenreich antigen core of mucin-type glycoproteins (39)), wheat germ agglutinin (which binds terminal GlcNAc (40) and, with lower affinity, sialic acid (41)), and Sambucus nigra lectin (SNA, which binds sialic acids (42)) indicated that GALE−/− cells indeed have reduced levels of each species compared with control cells (Fig. 2A). Consistent with these observations, monosaccharide composition analysis revealed a substantial decrease in total sialic acid, Gal, and GalNAc levels in glycans isolated from GALE−/− cells compared with controls (Fig. 2B).

We next profiled global glycolipids and protein N- and O-linked glycans via LC-MS. GALE−/− and control cells bore similar levels of many lipids and glycolipid precursors, such as phosphatidylinositol, ceramide, and cardiolipin (Figs. S1–S4). However, the levels of Gal/GalNAc-containing glycolipids, such as sulfatides and several gangliosides, were greatly reduced or undetectable in GALE−/− cells compared with controls (Fig. 2C and Figs. S2 and S4). These results demonstrate the importance of GALE in maintaining the glycolipidome.

In parallel, we analyzed N- and O-linked glycans from cell-surface glycoproteins. Consistent with our lectin staining results, we observed striking deficiencies in both mucin-type O-glycoproteins and Gal/GalNAc-containing N-linked glycan structures in GALE−/− cells (Figs. 3 and 4 and Figs. S5–S8). Gal-responsive defects in glycoprotein synthesis have been observed in galactosemia subtypes, caused by mutations in other Leloir pathway enzymes (43), but relatively little is known about how loss of GALE impacts glycan synthesis in the presence of Gal. To test the importance of GALE in this context, we analyzed the impact of Gal supplementation on the N- and O-linked glycan profiles of GALE−/− cells. We found that cells treated with Gal, but not those treated with mannitol (a non-

---

**Figure 1. Human GALE is required for NS metabolism.** A, human GALE epimerizes two pairs of NSs, UDP-Gal/UDP-Glc and UDP-GalNAc/UDP-GlcnAc. The major routes of UDP-Gal and UDP-GalNAc biosynthesis from monosaccharide salvage are outlined. UDP-Glc and UDP-GlcNAc can be biosynthesized from glucose. AGK1, UDP-GalNAc pyrophosphorylase; GALK, galactokinase; GALT, galactose-1-phosphate uridylyltransferase; HBPer, hexosamine biosynthetic pathway; UGDP, UDP-Glc biosynthetic pathway. B, GALE was deleted using CRISPR/Cas9 methods and one of three GALE-targeting sgRNAs (denoted 1–3) in 293T (left panel) and HeLa (right panel) cells. Single-cell-derived clones (denoted A or B) were lysed and analyzed by Western blotting. C, control and GALE−/− HeLa clones were treated with 250 or 500 μM Gal or mannitol for 72 h. Cell viability was measured by MTS assay and normalized to mannitol controls. n = 3 biological replicates. Error bars represent standard deviation. No statistically significant difference exists between control and GALE−/− cells (two-way ANOVA). D, control and GALE−/− HeLa cells (top panels) or 293T cells (bottom panels) were treated with 250 μM Gal or mannitol (osmolarity control) for 72 h, and UDP-Gal (left panels) and UDP-GalNAc (right panels) were quantified by high-performance anion exchange chromatography (HPAEC). n = 2 biological replicates for all measurements except HeLa UDP-GalNAc. Error bars represent standard deviation. Zero values indicate that the NS level falls below the detection limit of the HPAEC assays (0.15 μmol of UDP-Gal/mg protein and 3 μmol of UDP-GalNAc/mg protein at the cell lysate concentrations employed, as judged by serial dilution of standards and manual evaluation of the resulting peak), E, control or GALE−/− HeLa clones were treated with 250 μM Gal or mannitol for 72 h, and lysates were analyzed by Western blotting. GALK1 is the primary kinase for dietary Gal, whereas GALK2 is the primary kinase for GalNAc.
Human GALE is required for glycome function

Figure 2. Human GALE is required for maintenance of the glycoproteome and glycolipidome. A, control and GALE−/− 293T cells (left panels) and HeLa cells (right panels) were stained with fluorescently (FITC) tagged jacalin, SNA, or WGA lectins, and 10,000 cells from each sample were analyzed by flow cytometry. The predominant glycan ligand of each lectin is indicated between the corresponding panels. B, monosaccharide composition analysis of N- and O-linked glycans was performed on control and GALE−/− HeLa cells. C, summary of glycolipid species identified in control and GALE−/− 293T cells (left panel) and HeLa cells (right panel) via LC-MS. Red asterisks indicate glycolipid species dramatically reduced in GALE−/− cells. See also Figs. S1–S4.

metabolizable osmolyte control), closely resembled the glycans of control cells (Fig. 5 and Figs. S7–S10). We concluded that human GALE is required to support the biosynthesis of a broad range of glycoproteins and glycolipids.

GALE is required for cell-surface receptor glycosylation and function

We reasoned that altered glycosylation in GALE−/− cells might impact signaling through misglycosylated receptors. Consistent with this hypothesis, we observed substantial molecular weight shifts in several specific glycoproteins in GALE−/− cells compared with controls, including death receptors and integrins, major mediators of cell–matrix adhesion (Fig. 6). Gal supplementation suppressed these molecular weight changes in GALE−/− cells, indicating that they are caused by hypoglycosylation in the absence of GALE rather than an off-target or indirect effect of CRISPR manipulation (Fig. 6, A and B). Interestingly, although most integrins are glycoproteins (44, 45), only a subset was impacted by GALE deletion, suggesting specific roles of GALE activity in the biosynthesis of particular glycoconjugates (Fig. 6B). Our LC-MS studies indicated a relatively modest role of GALE in global N-glycan biosynthesis compared with O-glycans (Figs. 3 and 4). However, several key surface receptors, including Fas and integrin β3, exhibited aberrant N-glycoforms, as treatment with the glycosidase PNGase F, which cleaves N-glycans (46), restored these proteins to their predicted molecular weights in both control and GALE−/− cells (Fig. 6C).

To determine whether GALE is required to support glycoprotein function, we focused on the death receptor Fas as a model. Fas trimerization and activation by FasL trigger the formation of the death-inducing signaling complex, which recruits and activates upstream caspases, ultimately leading to downstream caspase-3 activation and apoptotic death (47, 48). No role of GALE or NS metabolism has been reported previously for death receptor signaling, but prior work has demonstrated that changes in Fas sialylation affect death-inducing signaling complex formation and the apoptotic cascade (49). Therefore, we hypothesized that Fas hypoglycosylation might affect cell death signaling in GALE−/− cells.

Neither GALE deletion nor Gal treatment altered the cell-surface expression of Fas (Fig. 7A). Interestingly, however, GALE−/− cells were significantly sensitized to FasL-induced killing (Fig. 7B). This result reflects a specific effect on FasL-induced death rather than general susceptibility to apoptosis because no analogous effect was observed when cells were treated with the broad-spectrum serine/threonine kinase inhibitor staurosporine (Fig. 7C). Next, to confirm the mechanism of sensitization to FasL in GALE−/− cells, we examined the apoptotic executioner caspase-3 (47). Compared with controls, GALE−/− cells exhibited increased caspase-3 cleavage (indicative of its activation) at early time points after FasL exposure (Fig. 7D). Finally, we examined the GALE-dependent glycan determinants that influence Fas signaling. Prior work by Bellis and colleagues demonstrated that up-regulation of the ST6Gal-I sialyltransferase in tumor cells potentiates Fas sialylation, reducing its responsiveness to ligand activation (49). Based on these reports and our monosaccharide composition and glycoprotein profiling data (Figs. 2, A and B, and 3–5), we hypothesized that the hypersensitivity of GALE−/− cells to FasL was caused by Fas hyposialylation. Consistent
with this idea, Gal supplementation reversed the sensitivity to FasL in \textit{GALE}^{−/−} cells (Fig. 7E), indicating a GALE-dependent causal link between receptor glycosylation (Figs. 3, 4, and 6, A and C) and activity (Fig. 7). Taken together, these results demonstrate that GALE is required to support the biosynthesis of sialylated N-glycans on Fas and other surface proteins and that loss of GALE function dysregulates glyco-protein receptor signaling.

**Discussion**

Regulation of human NS levels has profound implications for normal physiology and disease, but it remains poorly under-
Human GALE is required for glycome function

A

293T N-Glycans

Control

GALE\textsuperscript{−/−}

B

HeLa N-Glycans

Control

GALE\textsuperscript{−/−}
stood. Our results shed new light on the role of GALE, a model NS metabolic enzyme, in the biosynthesis and function of a wide range of glycoconjugates.

**GALE governs human NS levels**

**GALE**−/− cells have significantly reduced levels of UDP-GalNAc and UDP-Gal compared with controls (Fig. 1D). Based on these observations, we propose that GALE is required for biosynthesis and balancing of these key NSs despite the presence of free Gal and Gal/GalNAc-containing glycoproteins in serum, which could hypothetically be salvaged in a GALE-independent manner (50, 51). Our results support some conclusions of prior studies performed in other systems. For example, consistent with the idea that GALE is required to balance NSs, and in agreement with data from galactosemic patients and earlier experimental models (32, 34, 52), we observed a large increase in UDP-Gal in **GALE**−/− cells in the presence of supplementary Gal (Fig. 1D). On the other hand, our results challenge some conclusions of prior work. For instance, in GALE-deficient human patients and some model systems, Gal is acutely toxic.

**Figure 4. Human GALE is required for global N-linked glycoprotein biosynthesis.** A, summary of N-glycan species identified in control and **GALE**−/− HeLa cells via LC-MS. m/z values are given for each species. See also Fig. S8. B, summary of N-glycan (left panel) and O-glycan (right panel) species identified by LC-MS in **GALE**−/− 293T cells treated with 250 µM Gal or mannitol (osmolarity control) for 72 h. m/z values are given for each species. See also Figs. S7 and S8.

**Figure 5. Gal supplementation restores protein glycosylation in **GALE**−/− cells.** A, summary of O-glycan (left panel) and N-glycan (right panel) species identified by LC-MS in **GALE**−/− HeLa cells treated with 250 µM Gal or mannitol (osmolarity control) for 72 h. m/z values are given for each species. See also Figs. S8 and S9. B, summary of O-glycan (left panel) and N-glycan (right panel) species identified by LC-MS in **GALE**−/− 293T cells treated with 250 µM Gal or mannitol (osmolarity control) for 72 h. m/z values are given for each species. See also Figs. S7 and S10.
leading to severe symptoms or impairing cell health and proliferation (34, 53, 54). It has been proposed that the accumulation of intermediate metabolites or toxic byproducts might account for these harmful effects (55). However, we found no evidence of Gal toxicity in our GALE/H11002 cell systems (Fig. 1C). It may be that the accumulation of intermediate metabolites affects only specific cell or tissue types, perhaps because of other differences in Gal metabolism. Testing this hypothesis will be an important focus of future studies.

**GALE is required to support glycoconjugate biosynthesis**

Although aberrant glycosylation has been reported in other subtypes of galactosemia (43, 56–63), little is known about how loss of GALE affects glycan synthesis in human cells in the presence or absence of supplementary Gal. Here we show that GALE deletion dramatically affects glycoconjugate biosynthesis with greatly reduced Gal, GalNAc, and sialic acid content in cell-surface glycans of GALE/H11002 cells (Fig. 2A and B), impacting both N- and O-linked glycoproteins (Fig. 3). Moreover, our glycolipid profiling suggests that GALE is essential for biosynthesis of such species as myelinating glycolipids, including lactosylceramide and sulfatides (Fig. 2C). GM3 ganglioside is a regulator of leptin signaling and has been linked to development of insulin resistance (64, 65), sulfatides are major components of myelin and are believed to play crucial roles in neuronal differentiation (66, 67), and deficiencies in lactosylceramide biosynthesis cause locomotor deficits and abnormal brain development in mice (68). Therefore, GALE-dependent glycolipid biosynthesis may be required for normal nutrient responses and neuronal physiology in vivo. Our data may also provide a functional explanation for the previously reported postprandial transcriptional up-regulation of GALE in multiple tissue types (14, 25), suggesting that GALE could be critical for balancing NS pools and supporting glycoprotein and glycolipid biosynthesis after feeding.

Our results may also have unexpected implications for our understanding of human cell metabolism. For example, we observed that Gal supplementation largely restored biosynthe-
Figure 7. GALE is required for Fas N-glycosylation and function. A, control or GALE \(^{-/-}\) HeLa cell clones were treated with 250 \(\mu\)M Gal or mannitol for 72 h, stained with an anti-Fas antibody, and analyzed by flow cytometry. B, control and GALE \(^{-/-}\) HeLa cell clones were treated with the indicated concentrations of FasL for 24 h, and cell viability was measured by MTS assay. \(n = 3\) biological replicates. Error bars represent mean \(\pm\) S.E. \(p < 0.05\) for all FasL concentrations of 6 ng/ml or more, comparing control with GALE \(^{-/-}\) (two-way ANOVA, post hoc one-way ANOVA). C, control or GALE \(^{-/-}\) HeLa cell clones were treated with the indicated concentrations of staurosporine for 24 h, and cell viability was measured by MTS assay. \(n = 3\) biological replicates. Error bars represent S.E. D, control and GALE \(^{-/-}\) HeLa cell clones were treated with 2.5 ng/ml FasL for the indicated times, and lysates were analyzed by Western blotting. E, control or GALE \(^{-/-}\) HeLa clones were treated with 250 \(\mu\)M mannitol or Gal for 72 h and then with the indicated concentrations of FasL for an additional 24 h. Cell viability was measured by MTS assay. \(n = 3\) biological replicates. Error bars represent S.E. \(p < 0.05\) comparing mannitol-treated versus Gal-treated GALE \(^{-/-}\) cells at 5.5 ng/ml and 9.1 ng/ml FasL (three-way ANOVA, post hoc Tukey’s honest significant difference test).
**Human GALE is required for glycome function**

sis of UDP-GalNAc– and GalNAc-bearing glycans in GALE−/− cells (Figs. 1D and 5). These results were surprising because Gal is thought not to enter the well-characterized pathway for UDP-GalNAc biosynthesis (69, 70). We suggest two possible explanations for these observations. First, Gal supplementation may up-regulate the activity of salvage enzymes such as GALK1 and2, allowing cells to more efficiently recycle GalNAc monosaccharides from serum glycoproteins. Our results indicate that expression of GALK1 and GALK2 is unaffected by Gal treatment or GALE deletion (Fig. 1E), but future studies of GALK enzymatic activity will be needed to further test this hypothesis. Second, very high levels of Gal may result in its noncanonical entry into the hexosamine biosynthetic pathway, which biosynthesizes UDP-GlcNAc from Glc. In this scenario, sufficient UDP-GalNAc may be produced to restore glycoprotein biosynthesis. This hypothesis remains to be tested, but significant substrate promiscuity has been documented previously in mammalian hexosamine metabolism (71–73). Experiments are ongoing to investigate these two mutually compatible possibilities.

**GALE loss triggers receptor hypoglycosylation and dysfunction**

Our results demonstrate that GALE is required to support cell-surface receptor signaling even in nutrient-replete human cells, with significant effects on death receptor function (Fig. 7). Aberrant glycosylation has long been known to affect apoptotic receptor signaling. For example, oncogene activation up-regulates sialyltransferase expression and glycoprotein sialylation in colon adenocarcinomas, promoting cell migration and resistance to galectin-mediated apoptosis (74–76). Similarly, hyper-sialylation of Fas by ST6Gal-I protects tumor cells from Fas-mediated apoptosis (49). Given the dramatic loss of global sialylation in GALE−/− cells (Figs. 2, A and B, 3, and 4), we propose that Fas hyposialylation accounts for their hypersensitivity to FasL-induced apoptosis (Fig. 7B). Consistent with this notion, we observed GALE-dependent differences in FasL-mediated caspase-3 activation (Fig. 7D). Importantly, however, these results are not attributable to a general predisposition to apoptosis because no such hypersensitivity was observed in response to staurosporine (Fig. 7C). The effect of Gal supplementation on FasL response in GALE−/− cells is less pronounced at high FasL doses (Fig. 7E). This observation may be due to subtle variations in Fas N-glycosylation between Gal-treated control and GALE−/− cells and/or glycans-independent activation of Fas above a certain threshold concentration of FasL.

Beyond Fas, we also observed aberrant glycosylation of a subset of integrins in GALE−/− cells (Fig. 6, B and C). Glycosylation is well-known to impact the function of several integrins, particularly β3 (75, 77–84), and a very recent study suggested that GALE in particular may be necessary for integrin β3 function in platelet homeostasis (29). Based on this work and our own results, we speculate that GALE activity may be required in some contexts for normal integrin-mediated attachment to the extracellular matrix, cell adhesion and migration, or tissue homeostasis. Experiments are underway to test this hypothesis.

Finally, our results may have implications for understanding global protein N-glycosylation in both model systems and galactosemic patients. Past studies of mammalian GALE have largely focused on its role in O-glycan biosynthesis (35, 85–87). Therefore, it is especially noteworthy that we discovered alterations in the N-glycans of several cell-surface receptors (Fig. 6C). Altered N-glycans have been implicated in other subtypes of galactosemia based on observations in both human patients (43) and animal models (56). However, the role of mammalian GALE in supporting N-glycan biosynthesis has received little attention in any clinical or experimental context. We propose that altered N-glycans may contribute to the pathology of GALE-deficient galactosemia and that GALE may play a critical role in healthy tissue under normal conditions that trigger glycosylation changes, such as feeding or stress (14, 15).

**Conclusions**

NS metabolic enzymes have been extensively characterized at the biochemical level. However, the mechanistic basis and functional effects of dynamic changes in NS pools in cells and organisms remain poorly understood. We deleted GALE, a key node in NS metabolism, in human cell systems as a model for NS dysregulation. Our data demonstrate that human GALE is required for normal glycoconjugate biosynthesis and receptor signaling even in nutrient-replete cells. Moreover, we anticipate that the dramatic absence of cell-surface Gal, GalNAc, and sialic acid in GALE−/− cells, combined with the ability to restore normal glycosylation with simple Gal supplementation, will make GALE−/− cells an attractive model system for studying glycan function in normal cell physiology, metabolic syndrome, thrombocytopenia, and galactosemia.

**Experimental procedures**

**Cell culture**

293T and HeLa cells were cultured in DMEM containing 10% FBS, 100 g/ml streptomycin, and 100 units/ml penicillin in 5% CO2 at 37 °C. For monosaccharide supplementation experiments, cells were preconditioned with 250 μM mannitol or Gal (Sigma-Aldrich) for 72 h, with replenishment of monosaccharide every 24 h.

**Generation of GALE−/− cell lines**

GALE−/− HeLa and 293T cell lines were constructed essentially as described previously (88). Briefly, cells at ~50% confluency were stably transduced with a LentivCas9 virus obtained from the Duke Functional Genomics Facility in the presence of 4 μg/ml Polybrene. After overnight incubation, the medium was replaced, and cells were allowed to recover for 48 h before selection with 3 μg/ml (HeLa) or 5 μg/ml (293T) blasticidin. Cells were passaged until an uninfected control plate had no live cells remaining. Following selection, cells were infected with lentivirus bearing one of three single guide RNA (sgRNA) sequences targeting the GALE coding sequence or a “safe harbor” AAVS1-targeting control sgRNA (89). After sgRNA infection, cells were selected for stable sgRNA expression with 1.5 μg/ml (HeLa) or 0.5 μg/ml (293T) puromycin with continued presence of blasticidin. Following drug selection, clonal lines were generated via limiting dilution and assayed for GALE deletion via Western blotting. The GALE
sgRNA sequences used were as follows: GALE-1, GAGAAGG-TGCTGGTAACAGG; GALE-2, GAGAGCTGGCTACTTG-CCTG; GALE-3, GCCAGGTCCATGGCAGAGA.

**Western blotting**

Protein samples were quantified by BCA assay according to the manufacturer’s protocol (Thermo Fisher). Samples with equal protein amounts were separated by SDS-PAGE using standard methods (90) and electroblotted onto a PVDF membrane (Thermo Fisher, 88518). After blocking in Tris-buffered saline with 0.1% Tween (TBST) and 2.5% dry milk, the blots were incubated overnight at 4 °C in primary antibody with 5% BSA in TBST. The following day, the blots were washed three times in TBST, incubated with an appropriate horseradish peroxidase–conjugated secondary antibody (Southern Biotech, 1:5000) for 1 h at room temperature, washed three times in TBST, and developed via ECL according to the manufacturer’s instructions (WesternBright ECL, Advansta). The following primary antibodies were used: GALE (Abcam, ab 118033, 1:1000), tubulin (Sigma-Aldrich, T6074, 1:10,000), caspase-3 (Cell Signaling, 8G10, 1:1000), FAS-associated protein with death domain (Abclonal, A5819, C18C12, 1:1000), caspase-3 (Cell Signaling, 8G10, 1:1000), FAS-associated protein with death domain (Abclonal, A5819, C18C12, 1:1000), integrin α (Cell Signaling, 4705, 1:1000), integrin β (Santa Cruz, sc-13590, 1:1000), integrin β (Cell Signaling, D24A5, 1:1000), and GAPDH (Cell Signaling, 14C10, 1:5000).

**Flow cytometry**

For both lectin- and antibody-labeled flow cytometry, cells were harvested in 135 mM KCl/15 mM sodium citrate with 10 min of gentle rocking and resuspended in PBS with 2% BSA at 1 million cells/ml. For lectin labeling, cells were rotated for 30 min at 4 °C with fluorescent lectin in PBS/BSA, washed three times with PBS/BSA, and fixed with 2% paraformaldehyde for 20 min before analysis on a FACSCanto II cytometer (BD Biosciences). The lectins used were fluorescein-SNA (Vector Laboratories, FL-1201, 50 μg/10^6 cells), fluorescein-wheat germ agglutinin (Vector Laboratories, FL-1201, 50 μg/10^6 cells), and fluorescein-jacalin (Vector Laboratories, FL-1121, 50 μg/10^6 cells). For antibody labeling, aliquots of cells were incubated with primary antibody for 30 min at 4 °C and then washed three times with PBS/BSA. Then the cells were washed twice with 2% BSA/PBS and incubated with a secondary antibody for 30 min. After the final incubation, the cells were fixed with 2% paraformaldehyde for 20 min before analysis on a FACSCanto II cytometer (BD Biosciences). The antibodies used were Fas (Biolegend, 3056020, 0.5 μg/10^6 cells) and goat anti-mouse Alexa Fluor 488 (Thermo, A11001, 1 μg/10^6 cells).

**Glycolipid profiling**

Lipid extraction was performed using a modified Bligh-Dyer method (91). Briefly, cell pellets were resuspended in 1.6 ml of PBS and transferred into a 17-ml glass tube with a Teflon-lined cap. Then 4 ml of methanol and 2 ml of chloroform were added to create a single-phase Bligh-Dyer solution (chloroform:methanol:PBS, 1:20:8). The mixture was vigorously vortexed for 2 min and then sonicated in a bath water at room temperature for 20 min. After centrifugation at 3000 × g for 10 min, supernatants were transferred to fresh glass tubes and acidified by adding 100 μl of 37% HCl. After mixing, acidified solutions were converted into two-phase Bligh-Dyer systems by adding 2 ml of PBS and 2 ml of chloroform. After centrifugation at 3000 × g for 10 min, the lower phase was collected and dried under nitrogen. Lipid extracts were stored at −20 °C until LC-MS analysis. For lipidomic analysis, samples were dissolved in 200 μl of solution of chloroform:methanol (2:1), and 20 μl was injected for normal-phase LC-MS analysis.

Normal-phase LC was performed on an Agilent 1200 Quaternary LC system equipped with an Ascentis silica HPLC column (5 μm, 25 cm × 2.1 mm, Sigma-Aldrich). Mobile phase A was chloroform:methanol:aqueous NH₄OH (800:195:5 by volume), mobile phase B was chloroform:methanol:water:aqueous NH₄OH (600:340:50:5 by volume), and mobile phase C was chloroform:methanol:water:aqueous NH₄OH (450:450:95:5 by volume). The elution was performed as follows. 100% mobile phase A was held isocratically for 2 min and then linearly increased to 100% mobile phase B over 14 min and held at 100% B for 11 min. The gradient was then changed to 100% mobile phase C over 3 min, held at 100% C for 3 min, and finally returned to 100% A over 0.5 min and held at 100% A for 5 min. The LC eluent (total flow rate of 300 μL/min) was introduced into the electrospray ionization source of a high-resolution TripleTOF 5600 mass spectrometer (Sciex). The instrument settings for negative-ion electrospray ionization and MS/MS analysis of lipid species were as follows: ion spray voltage = −4500 V, curtain gas = 20 psi, ion source gas 1 = 20 psi, declustering potential = −55 V, and focusing potential = −150 V. MS/MS analysis used nitrogen as the collision gas. Data analysis was performed −55 V; FP, using Analyst TF1.5 software (Sciex).

**Glycan profiling**

Frozen cell pellets were resuspended in methanol:water (4:1.5) and sheared using a 20-gauge needle-equipped syringe. Delipidation was achieved by adding chloroform to a final ratio of 2:4:1.5 chloroform:methanol:water. Samples were incubated for 2 h, centrifuged, decanted, and incubated in the same chloroform:methanol:water mixture overnight. The next day, samples were centrifuged, resuspended in 4:1 acetone:water, and incubated on ice for 15 min. The samples were centrifuged, and the supernatant was decanted and incubated with acetone:water. Delipidated protein was dried under nitrogen and stored at −20 °C until analysis.

For N- and O-glycan analysis, 2–4 mg of dried protein powder was used per sample. N- and O-glycans were released enzymatically or chemically, respectively, and isolated as described previously (92). Following cleanup, glycans were permethylated as described previously (93), dried under nitrogen, and stored at −20 °C until analysis.

Permethylated glycans were resuspended and mixed with an internal standard before analysis via reverse-phase LC-MS/MS on a Thermo Scientific Velos Pro mass spectrometer as described previously (92). Glycan structures were manually interpreted based on in-house fragmentation rules, augmented by GlycoWorkbench and GRITS Toolbox semiautomated soft-
Human GALE is required for glycome function

ware solutions (94, 95). All glycan structures are depicted using standard symbol nomenclature for glycobiology (96).

Glycan monosaccharide analysis

Complete hydrolysis of isolated N- and O-glycans to monosaccharides was performed using 2 M TFA prior to analysis by HPAEC with pulsed amperometric detection (PAD). 100 μg of dry glycan sample was dissolved in 50 μl of ultrapure water and 50 μl of 4 M TFA and mixed thoroughly. The samples were hydrolyzed at 100 °C for 4 h. The hydrolyzed samples were cooled to room temperature and then centrifuged at 2000 rpm for 2 min. Acid was removed by complete evaporation under dry nitrogen flush, followed by two rounds of coevaporation with 100 μl of 50% isopropyl alcohol each time. Dry samples were resuspended in 142 μl of ultrapure water, and 70 μg of sample was injected for HPAEC-PAD analysis.

For neutral and amino sugar analysis, HPAEC-PAD profiling was performed on a Dionex ICS-3000 system equipped with a CarboPac PA1 column (4 × 250 mm), guard column (4 × 50 mm), and PAD using standard Quad waveform supplied by the manufacturer. An isocratic mixture of 19 mM NaOH with 0.95 mM NaOAc was used at a flow rate of 1 ml/min for 20 min. Neutral and amino sugars were identified and quantified by comparison with an authentic standard mixture of L-fucose, D-galactosamine, D-glucosamine, D-galactose, D-glucose, and D-mannose using Thermo Scientific Chromeleon software (version 6.8).

For sialic acid analysis, 50 μg of sample was hydrolyzed at 80 °C using 2 M acetic acid for 3 h. Released sialic acids were isolated by spin filtration using a 3000-kDa molecular mass cut-off centrifugal device (Nanosep 3K Omega, PALL Life Sciences, OD003C34). The flow-through containing released sialic acid was dried and derivatized using 1,2-diamino-4,5-methylene-dioxo benzene (DMB) (Sigma-Aldrich, D4784-10MG) as described previously (97). Fluorescent DMB-derivatized sialic acids were analyzed by reverse-phase HPLC using a Thermo Dionex UltiMate 3000 system equipped with a fluorescence detector. Samples were isocratically eluted with 9% acetonitrile (9%) and 7% methanol in ultrapure water over 30 min using an Acclaim 120-C18 column (4.6 × 250 mm, Dionex) at a flow rate of 0.9 ml/min. The excitation and emission wavelengths were set at 373 nm and 448 nm, respectively. DMB-derivatized sialic acids were identified and quantified by comparing the elution times and peak areas with known authentic standards of N-acetyllactosamine and N-acetylneuraminic acid using Chromeleon software (version 6.8).

Cell viability assays

Cells were plated into 96-well plates at 5000 cells/well in phenol red–free DMEM and allowed to recover for 24 h. FasL (Adipogen, AG-40B-0130-C010) or staurosporine (LC Labs, S-9300, 0.1–0.2 μM) was added and incubated for the indicated times. Then cell viability was assessed by adding soluble formazan (MTS assay, Promega) at a 1:1 dilution according to the manufacturer's protocol and incubating for 1 h at 37 °C, 5% CO2 before measuring absorbance at 490 nm.

NS analysis

Cells were cultured to confluence in 10-cm culture dishes, detached using 0.25% trypsin at 37 °C, and washed three times with PBS at 4 °C. Cells were lysed in methanol on dry ice, vigorously vortexed, and centrifuged to pellet proteinaceous solids. Pellets were resuspended in 8 M urea, and total protein was quantified by BCA assay. Methanol supernatants (containing NSs) were SpeedVac-dried and resuspended in 80 mM Tris-HCl (pH 7.4). Samples were separated on a Dionex CarboPac PA1 column (Thermo) using a Dionex ICS-5000+ SP HPAEC instrument and photodiode array. 10 μl of each sample was injected onto the column after pre-equilibration with 1 mM NaOH (solvent A). Samples were eluted at a flow rate of 1 ml/min using solvent A and solvent B (1 mM NaOH and 1 mM NaOAc) as follows: 0–100% B for 0–28 min and 100% B for 2 min. Samples were quantified using absorbance at 260 nm and compared with a series of authentic UDP-Gal or UDP-GalNAc standards at known concentrations (Sigma-Aldrich). Peak areas were integrated using Chromelon software, and cellular NS concentrations were calculated using standard curves and total protein amounts.

Quantification and statistical analysis

No randomization was performed for these studies. Quantitative experiments (e.g. MTS viability assays) were performed with a minimum of three biological replicates originating from independent cultures; for HPAEC metabolite analysis, a minimum of two biological replicates from independent cultures was employed. The number of biological replicates and statistical tests used are given in the figure legends. All Western blots are representative of at least two experiments from biologically independent samples.

Author contributions—A. B., A. F., C. D., N. N., C. R., and Z. G. investigation; A. B. and M. B. methodology; A. B. and M. B. writing—original draft; A. B., A. F., and M. B. writing-review and editing; Z. G., J. J. K., L. W., and M. B. funding acquisition; J. J. K., L. W., and M. B. supervision; M. B. conceptualization.

Acknowledgments—We thank Dr. So Young Kim and the Duke Functional Genomics Facility staff for designing and testing sgRNAs, Abhij Chhetri and Dr. Kenichi Yokoyama for training and assistance with HPAEC NS quantification, Dr. Biswa Choudhury and the UCSD Glycotechnology core facility for monosaccharide composition analysis, and Boyce laboratory members for helpful discussions.

References

1. Broussard, A. C., and Boyce, M. (2019) Life is sweet: the cell biology of glycoconjugates. Mol. Biol. Cell 30, 525–529 CrossRef Medline
2. Freeze, H., Hart, G., and Schnaar, R. (2017) Glycosylation precursors. In Essentials of Glycobiology (Varki, A., Cummings, R. D., Esko, J. D., and Freeze, H. H. eds) 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
3. Janik, M. E., Lityńska, A., and Vereecken, P. (2010) Cell migration: the role of integrin glycosylation. Biochim. Biophys. Acta 1800, 545–555 CrossRef Medline
4. Moran, A. P., Gupta, A., and Joshi, L. (2011) Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 60, 1412–1425 CrossRef Medline
Human GALE is required for glycome function

14. Deng, Y., Wang, Z. V., Tao, C., Gao, N., Holland, W. L., Ferdous, A., Repa, J. D., Freeze, H. H., Stanley, P., Bertozzi, C. R., Hart, G. W., and Etzler, M. E. eds) 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

15. Wang, Z. V., Deng, Y., Gao, N., Pedrozo, Z., Li, D. L., Morales, C. R., Crivolli, A., Luo, X., Tan, W., Jiang, N., Lehrman, M. A., Rothermel, B. A., Lee, A. H., Lavandero, S., Mammen, P. P. A., et al. (2014) Spliced X-box-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 156, 1179–1192 CrossRef Medline

16. Dennis, J. W., and Brewer, C. F. (2013) Density-dependent lectin-glycan interactions as a paradigm for conditional regulation by posttranslational modifications. Mol. Cell Proteomics 12, 913–920 CrossRef Medline

17. Lau, K. S., Partridge, A. E., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., and Dennis, J. W. (2007) Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129, 123–134 CrossRef Medline

18. Levine, Z. G., and Walker, S. (2016) The biochemistry of O-GlcNAc transferase: which functions make it essential in mammalian cells? Annu. Rev. Biochem. 85, 631–657

19. Moremen, K. W., Tiemeyer, M., and Nairn, A. V. (2012) Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13, 448–462 CrossRef Medline

20. Shen, D. L., Gloster, T. M., Yuzwa, S. A., and Vocadlo, D. J. (2012) Insights into O-linked N-acetylgalcosamine (O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates. J. Biol. Chem. 287, 15395–15408 CrossRef Medline

21. Ryczyk, M. C., Pawling, J., Chen, R., Rahman, A. M. A., Yau, K., Copeland, J. K., Zhang, C., Surendra, A., Guttman, D. S., Figueys, D., and Dennis, J. W. (2016) Metabolic reprogramming by hexosamine biosynthetic and Golgi N-glycan branching pathways. Sci. Rep. 6, 23043 CrossRef Medline

22. Frey, P. A. (1996) The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J. 10, 461–470 CrossRef Medline

23. Schulz, J. M., Watson, A. L., Sanders, R., Ross, K. L., Thoden, J. B., Holden, H. M., and Fridovich-Keil, J. L. (2004) Determinants of function and substrate specificity in human UDP-galactose 4'-epimerase. J. Biol. Chem. 279, 32796–32803 CrossRef Medline

24. Thoden, J. B., Wohlers, T. M., Fridovich-Keil, J. L., and Holden, H. M. (2001) Human UDP-galactose 4-epimerase: accommodation of UDP-N-acetylgalcosamine within the active site. J. Biol. Chem. 276, 15131–15136 CrossRef Medline

25. Williams, K. W., Liu, T., Kong, X., Fukushima, D., Deng, Y., Berglund, E. D., Deng, Z., Gao, Y., Liu, T., Sohn, J.-W., Jia, L., Fujikawa, T., Kohno, D., Scott, M. M., Lee, S., et al. (2014) Xbp1s in Pomc neurons connects ER stress with energy balance and glucose homeostasis. Cell Metab. 20, 471–482 CrossRef Medline

26. Zhu, Y., Zhao, S., Deng, Y., Gordillo, R., Ghaben, A. L., Shao, M., Zhang, F., Xu, P., Li, Y., Cao, H., Zagonikto, O., Scott, D. A., Gupta, R. K., Xing, C., Zhang, B. B., et al. (2017) Hepatic GALE regulates whole-body glucose homeostasis by modulating TIF3 expression. Diabetes. 66, 2789–2799 CrossRef Medline

27. Gitzelmann, R. (1995) Galactose-1-phosphate in the pathophysiology of galactosemia. Eur. J. Pediatr. 154, 545–549 CrossRef Medline

28. Fridovich-Keil, J., Bean, L., He, M., and Schroer, R. (2016) Epimerase deficiency galactosemia. Genviews Medline

29. Seo, A., Gulsuner, S., Pierce, S., Ben-Harosh, M., Shalev, H., Walsh, T., Krasnov, T., Dgany, O., Doulavot, S., Tamary, H., Shimamura, A., and King, M.-C. (2019) Inherited thrombocytopenia associated with mutation of UDP-galactose-4-epimerase (GALE). Hum. Mol. Genet. 28, 133–142 CrossRef Medline

30. Holden, H. M., Raymond, I., and Thoden, J. B. (2003) Structure and function of enzymes of the Leboi pathway for galactose metabolism. J. Biol. Chem. 278, 43885–43888 CrossRef Medline

31. Oopeno, K. K., Schulz, J. M., Vargas, C. A., Orton, C. S., Epstein, M. P., Schnur, R. E., Scaglia, F., Berry, G. T., Gottesman, G. S., Ficiciglo, C., Slonin, A. E., Schroer, R. I., Yu, C., Rangel, V. E., Keenan, J. M., et al. (2006) Epimerase-deficiency galactosemia is not a binary condition. Am. J. Hum. Genet. 78, 89–102 CrossRef Medline

32. Schulz, J. M., Ross, K. L., Malmstrom, K., Krieger, M., and Fridovich-Keil, J. L. (2005) Mediators of galactose sensitivity in UDP-galactose 4’-epimerase-impaired mammalian cells. J. Biol. Chem. 280, 13493–13502 CrossRef Medline

33. Walter, J. H., Roberts, E. R., Besley, G. T., Wraith, J. E., Cleary, M. A., Holton, J. B., and MacFaul, R. (1999) Generalised uridine diphosphategalactose-4-epimerase deficiency. Arch. Dis. Child. 80, 374–376 CrossRef Medline

34. Sanders, R. D., Sefton, J. M., Moberg, K. H., and Fridovich-Keil, J. L. (2010) UDP-galactose 4’ epimerase (GALE) is essential for development of Drosophila melanogaster. Dis. Model. Mech. 3, 628–638 CrossRef Medline

35. Kingsley, D. M., Kozarsky, K. F., Hobbie, L., and Krieger, M. (1986) Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell 44, 749–759 CrossRef Medline

36. Hang, H. C., and Bertozzi, C. R. (2005) The chemistry and biology of mucin-type O-linked glycosylation. Bioorg. Med. Chem. 13, 5021–5034 CrossRef Medline

37. Kolter, T., Proia, R. L., and Sandhoff, K. (2002) Combinatorial ganglioside biosynthesis. J. Biol. Chem. 277, 25859–25862 CrossRef Medline

38. Harduin-Lepers, A, Mollicone, R., Delannoy, P., and Oriol, R. (2005) The lectin recognizes the Neu5Ac(sialic acid) of the wheat germ agglutinin with sialoglycoproteins: the role of sialic acid. Glycobiology 15, 805–817 CrossRef Medline

39. Sankaranarayanan, R., Sekar, K., Banerjee, R., Sharma, V., Surolia, A., and Vijayan, M. (1996) A novel mode of carbohydrate recognition in jacalin, a Moraceae plant lectin with a O-linked glycosylation. Nat. Struct. Biol. 3, 596–603 CrossRef Medline

40. Nagata, Y., and Burger, M. M. (1974) Wheat germ agglutinin molecular characteristics and specificity for sugar binding. J. Biol. Chem. 249, 3116–3122 Medline

41. Bhavanandan, V. P., and Katlic, A. W. (1979) The interaction of wheat germ agglutinin with sialoglycoproteins: the role of sialic acid. J. Biol. Chem. 254, 4000–4008 Medline

42. Shibuya, N., Goldstein, I. J., Broekaert, W. F., Nsimba-Lubaki, M., Peeters, B., and Peumans, W. J. (1987) The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(α2–6)Gal/GalNAc sequence. J. Biol. Chem. 262, 1596–1601 Medline
Human GALE is required for glycome function

43. Liu, Y., Xia, B., Gleason, T. J., Castañeda, U., He, M., Berry, G. T., and Fridovich-Keil, J. L. (2012) N- and O-linked glycosylation of total plasma glycoproteins in galactosemia. *Mol. Genet. Metab.* **106**, 442–454 CrossRef Medline

44. Marsico, G., Russo, L., Quondamatteo, F., and Pandit, A. (2018) Glycosylation and integrin regulation in cancer. *Trends Cancer* **4**, 537–552 CrossRef Medline

45. Bhide, G. P., and Colley, K. J. (2017) Sialylation of Human GALE is required for glycome function.

46. Tarentino, A. L., Gómez, C. M., and Plummer, T. H., Jr. (1985) Deglycosylation of asparagine-linked glycans by peptide: N-glycosidase F. *Biochemistry* **24**, 4665–4671 CrossRef Medline

47. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *EMBO J.* **14**, 5579–5588 CrossRef Medline

48. Peter, M. E., and Krammer, P. H. (2003) The CD95 (APO-1/Fas) DISC and beyond. *Cell Death Differ.* **10**, 26–35 CrossRef Medline

49. Swindall, A. F., and Bellis, S. L. (2011) Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. *J. Biol. Chem.* **286**, 22982–22990 CrossRef Medline

50. Ichikawa, M., Scott, D. A., Losfeld, M.-E., and Freeze, H. H. (2014) The metabolic origins of mannose in glycoproteins. *J. Biol. Chem.* **289**, 6751–6761 CrossRef Medline

51. Fujita, N., Tamura, A., Higashidani, A., Tonozuka, T., Freeze, H. H., and Nishikawa, A. (2008) The relative contribution of mannose salvage pathways to glycosylation in PMI-deficient mouse embryonic fibroblast cells. *FEBS J.* **275**, 788–798 CrossRef Medline

52. Henderson, M. I., Holton, J. B., and MacFaul, R. (1983) Further observations in a case of uridine diphosphate galactose-4-epimerase deficiency with a severe clinical presentation. *J. Inherit. Metab. Dis.* **6**, 17–20 CrossRef Medline

53. Novelli, G., and Reichardt, J. K. (2000) Molecular basis of disorders of human galactose metabolism: past, present, and future. *Mol. Genet. Metab.* **71**, 62–65 CrossRef Medline

54. Brokate-Llanos, A. M., Monje, J. M., Murdoch, P. S., and Muñoz, M. J. (2014) Developmental defects in a Caenorhabditis elegans model for type III galactosia. *Genetics* **198**, 1559–1569 CrossRef Medline

55. Fridovich-Keil, J. L. (2006) Galactosemia: the good, the bad, and the unknown. *J. Cell Physiol.* **209**, 701–705 CrossRef Medline

56. Jumbo-Lucioni, P., Parkinson, W., and Broadie, K. (2014) Overelaborated synaptic architecture and reduced synaptomatrix glycosylation in a classic galactosemia disease model.

57. Haberland, C., Perou, M., Brunngruber, E. G., and Hof, H. (1971) The neuropathology of galactosemia: a histopathological and biochemical study. *J. Neuropathol. Exp. Neurol.* **30**, 431–447 CrossRef Medline

58. Witting, L. A., Haberland, C., and Brunngruber, E. G. (1972) Ganglioside patterns in galactosemia. *Clin. Chim. Acta.* **37**, 387–389 CrossRef Medline

59. Jaeken, J., Kint, J., and Spaepen, L. (1992) Serum lysosomal enzyme abnormalities in galactosemia. *Lancet* **340**, 1472–1473 CrossRef Medline

60. Petry, K., Greinin, H. T., Nudelman, E., Eisen, H., Hakomori, S., Levy, H. L., and Reichardt, J. K. (1991) Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or -acetylgalactosamine and accumulation of precursors in brain and lymphocytes. *Biochem. Med. Metab. Biol.* **46**, 93–104 CrossRef Medline

61. Stibler, H., von Döbeln, U., Kristiansson, B., and Guthenberg, C. (1997) Carbohydrate-deficient transferrin in galactosemia. *Acta Paediatr.* **86**, 1377–1378 CrossRef Medline

62. Charlwood, J., Clayton, P., Keir, G., Mian, N., and Winchester, B. (1998) Defective glycosylation of serum transferin in galactosemia. *Glycobiol.* **8**, 351–357 CrossRef Medline

63. Sturiale, L., Barone, R., Fiumara, A., Perez, M., Zaffanello, M., Sorge, G., Pavone, L., Tortorelli, S., O’Brien, J. F., Jaeken, J., and Garozzo, D. (2005) Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. *Glycobiology* **15**, 1268–1276 CrossRef Medline

64. Inamori, K., Ito, H., Tamura, Y., Nitta, T., Yang, X., Nihei, W., Shishido, F., Imazu, S., Tsukita, S., Yamada, T., Katagiri, H., and Inokuchi, I. (2018) Deficient gangloside synthesis restores responsiveness to leptin and melanocortin signaling in obese KKAy mice. *J. Lipid Res.* **59**, 1472–1481 CrossRef Medline

65. Li, S., Ohkawa, Y., Tokizane, K., Ohmi, Y., Banno, R., Furukawa, K., Kiya, H., and Furukawa, K. (2015) B-series gangliosides crucially regulate leptin secretion in adipose tissues. *Biochem. Biophys. Res. Commun.* **459**, 185–195 CrossRef Medline

66. Hirahara, Y., Wakabayashi, T., Mori, T., Koike, T., Yao, I., Tsuda, M., Honke, K., Gotoh, H., Ono, K., and Yamada, H. (2017) Sulfatide species with various fatty acid chains in oligodendrocytes at different developmental stages determined by imaging mass spectrometry. *J. Neurochem.* **140**, 435–450 CrossRef Medline

67. Palaviczini, J. P., Wang, C., Chen, L., Ahmarr, S., Higuera, J. D., Dupree, J. L., and Han, X. (2016) Novel molecular insights into the critical role of sulfatide in myelin maintenance/function. *J. Neurochem.* **139**, 40–54 CrossRef Medline
Human GALE is required for glycome function

Mol. Cell. Biol. 26, 3181–3193

Bellis, S. L. (2004) Variant glycosylation: an underappreciated regulatory mechanism for β1 integrins. Biochim. Biophys. Acta 1663, 52–60

Seales, E. C., Shaikh, F. M., Woodward-Grice, A. V., Aggarwal, P., McBrayer, A. C., Hennessy, K. M., and Bellis, S. L. (2005) A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering β1 integrin sialylation. J. Biol. Chem. 280, 37610–37615

Gu, J., Isaji, T., Sato, Y., Fukuda, T., and Gu, J. (2009) Importance of N-glycosylation on α5β1 integrin for its biological functions. Biol. Pharm. Bull. 32, 780–785

Isaji, T., Sato, Y., Fukuda, T., and Gu, J. (2009) N-glycosylation of the I-like domain of β1 integrin is essential for β1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for α5β1. J. Biol. Chem. 284, 12207–12216

Semel, A. C., Seales, E. C., Singhal, A., Eklund, E. A., Colley, K. J., and Bellis, S. L. (2002) Hyposialylation of Integrins stimulates the activity of myeloid fibronectin receptors. J. Biol. Chem. 277, 32830–32836

Termini, J. M., Silver, Z. A., Connor, B., Antonopoulos, A., Haslam, S. M., Dell, A., and Desrosiers, R. C. (2017) HEK293T cell lines defective for O-linked glycosylation. PLoS ONE. 12, e0179949

Blackburn, J. B., Kudlyk, T., Pokrovskaya, I., and Lupashin, V. V. (2018) More than just sugars: conserved oligomeric Golgi complex deficiency causes glycosylation-independent cellular defects. Traffic 19, 463–480

Hu, Y., Li, Z. F., Wu, X., and Lu, Q. (2011) Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on α-dystroglycan. PLoS ONE 6, e16866

Cox, N. J., Unlu, G., Bisnutt, B. J., Meister, T. R., Condon, B. M., Luo, P. M., Smith, T. J., Hanna, M., Chhetri, A., Soderblom, E. J., Audhya, A., Knapik, E. W., and Boyce, M. (2018) Dynamic glycosylation governs the vertebrate COPII protein trafficking pathway. Biochemistry 57, 91–107

Bellis, S. L. (2004) Variant glycosylation: an underappreciated regulatory mechanism for β1 integrins. Biochim. Biophys. Acta 1663, 52–60

Seales, E. C., Shaikh, F. M., Woodward-Grice, A. V., Aggarwal, P., McBrayer, A. C., Hennessy, K. M., and Bellis, S. L. (2005) A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering β1 integrin sialylation. J. Biol. Chem. 280, 37610–37615

Gu, J., Isaji, T., Sato, Y., Fukuda, T., and Gu, J. (2009) Importance of N-glycosylation on α5β1 integrin for its biological functions. Biol. Pharm. Bull. 32, 780–785

Isaji, T., Sato, Y., Fukuda, T., and Gu, J. (2009) N-glycosylation of the I-like domain of β1 integrin is essential for β1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for α5β1. J. Biol. Chem. 284, 12207–12216

Gu, J., Isaji, T., Sato, Y., Fukuda, T., and Gu, J. (2009) Importance of N-glycosylation on α5β1 integrin for its biological functions. Biol. Pharm. Bull. 32, 780–785

Bellis, S. L. (2002) Hyposialylation of Integrins stimulates the activity of myeloid fibronectin receptors. J. Biol. Chem. 277, 32830–32836

Termini, J. M., Silver, Z. A., Connor, B., Antonopoulos, A., Haslam, S. M., Dell, A., and Desrosiers, R. C. (2017) HEK293T cell lines defective for O-linked glycosylation. PLoS ONE. 12, e0179949

Blackburn, J. B., Kudlyk, T., Pokrovskaya, I., and Lupashin, V. V. (2018) More than just sugars: conserved oligomeric Golgi complex deficiency causes glycosylation-independent cellular defects. Traffic 19, 463–480

Hu, Y., Li, Z. F., Wu, X., and Lu, Q. (2011) Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on α-dystroglycan. PLoS ONE 6, e16866

Cox, N. J., Unlu, G., Bisnutt, B. J., Meister, T. R., Condon, B. M., Luo, P. M., Smith, T. J., Hanna, M., Chhetri, A., Soderblom, E. J., Audhya, A., Knapik, E. W., and Boyce, M. (2018) Dynamic glycosylation governs the vertebrate COPII protein trafficking pathway. Biochemistry 57, 91–107